title: [Hormone therapy of endometrial carcinoma].
abstract: Various hormone therapies for endometrial carcinoma have been reported in the literature using progestins, tamoxifen (anti-estrogen), danazol, Gn-RH etc. The response rates of these hormone therapies are reported to be approximately 30%, which is no longer superior to other types of treatment methods. On the other hand, endometrial carcinoma is considered to be one of hormone dependent tumors. Although sex steroid hormones play an important role in the mechanism of carcinogenesis and the progression of early and well-differentiated endometrial carcinoma, most of the advanced carcinomas treated by hormone therapy have transformed into hormone independent state. It is expected that endometrial hyperplasia and well-differentiated carcinoma especially in younger patients should be effective materials for hormone therapy.
authors.affiliation: Dept. of Obstetrics & Gynecology, Kitasato University School of Medicine. Sagamihara, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kuramoto
authors.forename: T
authors.initials: T
authors.lastname: Jobo
authors.forename: Y
authors.initials: Y
authors.lastname: Kato
authors.forename: K
authors.initials: K
authors.lastname: Tateoka
authors.forename: R
authors.initials: R
authors.lastname: Sato
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy; D011372:Progestins / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D011372:Progestins; D013629:Tamoxifen